Experienced in Infantile Neutropenia

Dr. Shawn E. Mccandless

Medical Genetics | Pediatrics
University Physicians Incorporated
13123 E 16th Ave, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Infantile Neutropenia
University Physicians Incorporated
13123 E 16th Ave, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shawn Mccandless is a Medical Genetics specialist and a Pediatrics provider in Aurora, Colorado. Dr. Mccandless is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Prader-Willi Syndrome, Urea Cycle Disorders (UCD), Pyruvate Decarboxylase Deficiency, and Pyruvate Dehydrogenase Deficiency. Dr. Mccandless is currently accepting new patients.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Infantile Neutropenia.

Specialties
Medical Genetics
Pediatrics
Licenses
Clinical Genetics in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIANS INCORPORATED
13123 E 16th Ave, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)
Enrollment Status: Recruiting
Publish Date: September 10, 2025
Intervention Type: Other
Longitudinal Study of Urea Cycle Disorders
Longitudinal Study of Urea Cycle Disorders
Enrollment Status: Recruiting
Publish Date: February 13, 2024
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Phase: Phase 4
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: DCCR (diazoxide choline controlled release tablets)
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Active_not_recruiting
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

57 Total Publications

ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.
ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.
Journal: Mitochondrion
Published: January 03, 2024
Similar Doctors
Experienced in Infantile Neutropenia
Dr. Eliza D. Blanchette
Pediatric Nephrology | Pediatrics | Neonatology
Experienced in Infantile Neutropenia
Dr. Eliza D. Blanchette
Pediatric Nephrology | Pediatrics | Neonatology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.1 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eliza Blanchette is a Pediatric Nephrologist and a Pediatrics provider in Aurora, Colorado. Dr. Blanchette is rated as an Experienced provider by MediFind in the treatment of Infantile Neutropenia. Her top areas of expertise are Infantile Neutropenia, Focal Segmental Glomerulosclerosis, Glomerulonephritis, High Potassium Level, and Kidney Transplant. Dr. Blanchette is currently accepting new patients.

Experienced in Infantile Neutropenia
Dr. Eric G. Benz
Pediatric Nephrology | Nephrology | Pediatrics
Experienced in Infantile Neutropenia
Dr. Eric G. Benz
Pediatric Nephrology | Nephrology | Pediatrics

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (0.1 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Eric Benz is a Pediatric Nephrologist and a Nephrologist in Aurora, Colorado. Dr. Benz is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Autosomal Recessive Polycystic Kidney Disease, Infantile Neutropenia, Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, and Kidney Transplant. Dr. Benz is currently accepting new patients.

Experienced in Infantile Neutropenia
Dr. Erwin W. Gelfand
Pediatrics
Experienced in Infantile Neutropenia
Dr. Erwin W. Gelfand
Pediatrics
1400 Jackson St, 
Denver, CO 
 (5.7 miles away)
303-388-4461
Languages Spoken:
English
See accepted insurances

Erwin Gelfand is a Pediatrics provider in Denver, Colorado. Dr. Gelfand is rated as an Advanced provider by MediFind in the treatment of Infantile Neutropenia. His top areas of expertise are Respiratory Syncytial Virus (RSV) Infection, Emphysema, Pignata Guarino Syndrome, and Infantile Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccandless's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile